DeepMed Research

Testosterone

Generic Name: Testosterone

Brand Names: Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Testopel, Vogelxo

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₈O_₂

CAS Number: 58-22-0

Unique Ingredient Identifier: 3XMK78S47O

Background: Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism. Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.

Testosterone was isolated from samples and also synthesized in 1935.

Indication: Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.

Associated Conditions: Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism, Idiopathic Hypogonadotropic Hypogonadism, Puberty, Delayed, Inoperable, metastatic Breast cancer

Clinical Trials

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

Phase 2

Recruiting

Conditions: Metastatic Prostate Cancer

Interventions: Drug: High dose testosterone

First Posted Date: 2021-08-18

Last Posted Date: 2024-08-21

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 51

Registration Number: NCT05011383

Locations: 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States
🇺🇸
VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States
🇺🇸
Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States

and more 14 locations

A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel

Phase 4

Conditions: Hypogonadism

Interventions: Drug: Natesto

First Posted Date: 2021-07-26

Last Posted Date: 2022-07-06

Lead Sponsor: Acerus Pharmaceuticals Corporation

Target Recruit Count: 218

Registration Number: NCT04976595

Locations: 🇺🇸
Eclipse Clinical Research, Tucson, Arizona, United States
🇺🇸
Preferred Research Partners, Little Rock, Arkansas, United States
🇺🇸
NYU Langone Health, New York, New York, United States

and more 27 locations

Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy

Phase 3

Recruiting

Conditions: Prostatic Neoplasms
Hypogonadism
Testosterone Deficiency

Interventions: Drug: Testosterone gel
Drug: Placebo

First Posted Date: 2021-04-06

Last Posted Date: 2025-05-02

Lead Sponsor: Canisius-Wilhelmina Hospital

Target Recruit Count: 140

Registration Number: NCT04833426

Locations: 🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱
Amsterdam UMC location VUmc, Amsterdam, Netherlands
🇳🇱
Rijnstate, Arnhem, Netherlands

and more 7 locations

Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study

Phase 3

Conditions: Disorder of Sex Development, 46,XY

Interventions: Drug: Testosterone gel
Drug: Placebo

First Posted Date: 2021-04-05

Last Posted Date: 2021-04-05

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 1

Registration Number: NCT04831099

Locations: 🇳🇱
Erasmus MC, Rotterdam, Zuid-Holland, Netherlands

Testosterone and Neurovascular Control in Humans

Not Applicable

Conditions: Healthy

Interventions: Drug: Cetrorelix Acetate
Drug: Testosterone gel

First Posted Date: 2021-03-26

Last Posted Date: 2021-03-26

Lead Sponsor: Western University, Canada

Target Recruit Count: 20

Registration Number: NCT04819204

Locations: 🇨🇦
the University of Western Ontario, London, Ontario, Canada

Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism

Phase 2

Recruiting

Conditions: Pain
Opioid Use
Hypogonadism, Male

Interventions: Drug: Testosterone Undecanoate 250 MG/ML
Drug: Placebo

First Posted Date: 2021-03-15

Last Posted Date: 2025-04-03

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 150

Registration Number: NCT04798469

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

The Effects of Natesto For Treatment Of Hypogonadism

Early Phase 1

Withdrawn

Conditions: Hypogonadism, Male
Infertility, Male
Testosterone Deficiency

Interventions: Drug: Natesto Nasal Product

First Posted Date: 2021-01-22

Last Posted Date: 2024-04-24

Lead Sponsor: Baylor College of Medicine

Registration Number: NCT04717362

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

Phase 4

Completed

Conditions: Long QT Syndrome
Abnormalities, Drug-Induced

Interventions: Drug: Progesterone
Drug: Ibutilide
Drug: Placebo
Drug: Testosterone

First Posted Date: 2020-12-19

Last Posted Date: 2025-04-29

Lead Sponsor: Indiana University

Target Recruit Count: 73

Registration Number: NCT04675788

Locations: 🇺🇸
Indiana Clinical Research Center, Indianapolis, Indiana, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Purdue University, Indianapolis, Indiana, United States

A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-845

Phase 1

Completed

Conditions: Hypogonadism

Interventions: Drug: D309
Drug: CKD-845

First Posted Date: 2020-12-17

Last Posted Date: 2022-09-28

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 47

Registration Number: NCT04673682

Locations: 🇰🇷
Jeonbuk University Hospital, Jeonju, Jeonbuk, Korea, Republic of

Effect of Testosterone Pretreatment in POR

Not Applicable

Completed

Conditions: Infertility

Interventions: Drug: Testosterone gel

First Posted Date: 2020-10-26

Last Posted Date: 2020-10-26

Lead Sponsor: Hanoi Medical University

Target Recruit Count: 165

Registration Number: NCT04602143

Locations: 🇻🇳
Hanoi Medical University, Vietnam, Hanoi, Vietnam

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy